新型抗凝药物的研究展望

被引：15

作者：

史旭波

白英

机构：

[1] 首都医科大学附属北京同仁医院心脏中心

来源：

中华关节外科杂志(电子版) | 2009年 / 3卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R973.2 [];

学科分类号：

摘要：

引用

收藏

页码：119 / 121

页数：3

相关论文

共 4 条

[1]

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial [J].

Kakkar, Ajay K. ;

Brenner, Benjamin ;

Dahl, Ola E. ;

Eriksson, Bengt I. ;

Mouret, Patrick ;

Muntz, Jim ;

Soglian, Andrea G. ;

Pap, Akos F. ;

Misselwitz, Frank ;

Haas, Sylvia .

LANCET, 2008, 372 (9632) :31-39

[2]

A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement [J].

Eriksson, Bengt I. ;

Borris, Lars C. ;

Dahl, Ola E. ;

Haas, Sylvia ;

Huisman, Menno V. ;

Kakkar, Ajay K. ;

Muehlhofer, Eva ;

Dierig, Christoph ;

Misselwitz, Frank ;

Kalebo, Peter .

CIRCULATION, 2006, 114 (22) :2374-2381

[3]

Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct Factor Xa inhibitor - Are not affected by aspirin [J].

Kubitza, Dagmar ;

Becka, Michael ;

Mueck, Wolfgang ;

Zuehlsdorf, Michael .

JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09) :981-990

[4]

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects [J].

Kubitza, D ;

Becka, M ;

Wensing, G ;

Voith, B ;

Zuehlsdorf, M .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (12) :873-880